Evidence map›Paper›PMID 40794125›Full record

ArticleInternational journal of clinical oncology2025

Clinical and biological impact of SNAT7 in lung adenocarcinoma: implications for prognosis and treatment.

Asato Hashinokuchi, Naoki Haratake, Yuya Ono, Takumi Tomonaga, Giacomo Bassi, Kyoto Matsudo, Fumihiko Kinoshita, Taichi Matsubara, Mikihiro Kohno, Tomoyoshi Takenaka and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Asato HashinokuchiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Naoki HaratakeDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Yuya OnoDepartment of Surgery, Kyushu University Beppu Hospital, Beppu, Oita, Japan.
Takumi TomonagaDepartment of Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Giacomo BassiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Kyoto MatsudoDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Fumihiko KinoshitaDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Taichi MatsubaraDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Mikihiro KohnoDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Tomoyoshi TakenakaDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan. takenaka.tomoyoshi.473@m.kyushu-u.ac.jp.ORCID http://orcid.org/0000-0002-0278-1854
Yoshinao OdaDepartment of Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Tomoharu YoshizumiDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlutamine metabolism plays a crucial role in cancer cell proliferation and modulates the tumour microenvironment. High expression of glutamine transporters is associated with poor prognosis in non-small cell lung cancer. SNAT7, encoded by SLC38A7, facilitates glutamine transport from lysosomes. However, its function and clinical significance in lung adenocarcinoma remain unclear. MATERIALS AND

methodsImmunohistochemistry (IHC) was performed with samples from 373 patients with completely resected lung adenocarcinoma, and the association between SNAT7 expression, clinicopathological features, and prognosis was examined. In addition, the biological findings were investigated in lung adenocarcinoma cell lines.

resultsBased on IHC analysis, we classified patients into high (n = 226, 60.6%) and low SNAT7 expression (n = 147, 39.4%) groups. High SNAT7 expression was substantially associated with male sex, smoking status, high maximum standardised uptake value, advanced pathological stage, and pleural, lymphatic, and vascular invasion, compared to low SNAT7 expression. Patients with high SNAT7 expression demonstrated substantially worse recurrence-free survival (RFS) and overall survival rates. Multivariable analysis revealed that high SNAT7 expression was an independent prognostic factor for RFS. In addition, SLC38A7 knockdown induced a decrease in proliferation with G1 arrest in lung adenocarcinoma cell lines.

conclusionOur findings demonstrate that SNAT7 plays a pivotal role in promoting tumour malignancy and is significantly associated with poor prognosis in lung adenocarcinoma. These findings suggest that SNAT7 is a potential therapeutic target in lung adenocarcinoma.

Indexed as

AdenocarcinomaAdenocarcinoma of LungAmino Acid Transport Systems, NeutralBiomarkers, TumorLung NeoplasmsAdultAgedCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisAmino Acid Transport Systems, NeutralBiomarkers, TumorCancer metabolismGlutamine transporterLung adenocarcinomaSLC38A7SNAT7

Identifiers

PMID40794125

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.